Literature DB >> 1701477

Identification of operationally overlapping and independent cross-reactive neutralization regions on human rotavirus VP4.

N Kobayashi1, K Taniguchi, S Urasawa.   

Abstract

Cross-reactive neutralization epitopes on VP4 of human rotavirus (HRV) were analyzed by the use of VP4-specific neutralizing monoclonal antibodies (N-MAbs) and MAb-resistant mutants. Seven anti-VP4 N-MAbs obtained in this study by using HRV serotypes 1 and 3 as immunizing antigens showed a variety of cross-reactivity patterns to 20 HRV strains with different serotype specificity in neutralization tests and a broader cross-reactivity to them was found for four N-MAbs in an enzyme-linked immunosorbent assay. On the basis of the reactivity patterns against rotaviruses in neutralization tests, these seven N-MAbs were classified into four groups. Cross-neutralization tests using a total of 12 pairs of MAbs and resistant mutants, including five pairs which had been prepared previously, showed that VP4 of HRV (strain KU) contained two independent antigenic regions. One, region C1, was recognized by a single MAb (YO-2C2) and the other was made up of two antigenic regions (C2 and C3) which overlapped operationally. Identification of amino acid substitution sites on VP4 of representative mutants of HRV strain KU indicated that amino acid positions 385 or 392 and 428 or 433 were critical for the C2 and C3 regions, respectively. These results suggested that regions C2 and C3 exist as conformational antigenic sites.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1701477     DOI: 10.1099/0022-1317-71-11-2615

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  23 in total

1.  The rhesus rotavirus VP4 sialic acid binding domain has a galectin fold with a novel carbohydrate binding site.

Authors:  Philip R Dormitzer; Zhen-Yu J Sun; Gerhard Wagner; Stephen C Harrison
Journal:  EMBO J       Date:  2002-03-01       Impact factor: 11.598

2.  Distribution of serotypes of human rotavirus in different populations.

Authors:  P A Woods; J Gentsch; V Gouvea; L Mata; M Santosham; Z S Bai; S Urasawa; R I Glass
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

3.  Isolation of human monoclonal antibodies that neutralize human rotavirus.

Authors:  Kyoko Higo-Moriguchi; Yasushi Akahori; Yoshitaka Iba; Yoshikazu Kurosawa; Koki Taniguchi
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

4.  Development, characterization, and diagnostic applications of monoclonal antibodies against bovine rotavirus.

Authors:  Y Al-Yousif; F Al-Majhdi; C Chard-Bergstrom; J Anderson; S Kapil
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

5.  Typing of human rotavirus VP4 by an enzyme immunoassay using monoclonal antibodies.

Authors:  B S Coulson
Journal:  J Clin Microbiol       Date:  1993-01       Impact factor: 5.948

6.  Nucleotide sequence and expression in E. coli of the complete P4 type VP4 from a G2 serotype human rotavirus.

Authors:  N P Mahajan; C D Rao
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

7.  Preparation and characterization of a neutralizing monoclonal antibody directed to VP4 of rotavirus strain K8 which has unique VP4 neutralization epitopes.

Authors:  N Kobayashi; K Taniguchi; T Urasawa; S Urasawa
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

8.  Comparison of enzyme immunoassay, PCR, and type-specific cDNA probe techniques for identification of group A rotavirus gene 4 types (P types).

Authors:  P J Masendycz; E A Palombo; R J Gorrell; R F Bishop
Journal:  J Clin Microbiol       Date:  1997-12       Impact factor: 5.948

9.  Serologic analysis of human rotavirus serotypes P1A and P2 by using monoclonal antibodies.

Authors:  L Padilla-Noriega; R Werner-Eckert; E R Mackow; M Gorziglia; G Larralde; K Taniguchi; H B Greenberg
Journal:  J Clin Microbiol       Date:  1993-03       Impact factor: 5.948

10.  Human rotavirus VP4 contains strain-specific, serotype-specific and cross-reactive neutralization sites.

Authors:  C D Kirkwood; R F Bishop; B S Coulson
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.